NCT06099782 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 147
- units
- Participants
- groups
- description
- In Treatment Crossover Period 1 participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \~2 years) for NSCLC.
- id
- BG000
- title
- Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV
- description
- In Treatment Crossover Period 1 participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \~2 years) for NSCLC.
- id
- BG001
- title
- Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.8
- value
- 59.7
- group Id
- BG001
- spread
- 12.5
- value
- 63.2
- group Id
- BG002
- spread
- 12.3
- value
- 61.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 57
- title
- Female
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 90
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 53
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 77
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 58
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 118
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 76
- group Id
- BG002
- value
- 147
- units
- Participants
- groups
- description
- In Treatment Crossover Period 1 participants first received pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles, followed by pembrolizumab IV for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \~2 years) for NSCLC.
- id
- BG000
- title
- Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV
- description
- In Treatment Crossover Period 1 participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \~2 years) for NSCLC.
- id
- BG001
- title
- Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.8
- value
- 59.7
- group Id
- BG001
- spread
- 12.5
- value
- 63.2
- group Id
- BG002
- spread
- 12.3
- value
- 61.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 28
- group Id
- BG002
- value
- 57
- title
- Female
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 90
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 53
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 77
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 58
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 118
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle